Scholar Rock/$SRRK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Scholar Rock
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Ticker
$SRRK
Sector
Primary listing
Employees
289
Headquarters
Website
Scholar Rock Metrics
BasicAdvanced
$5.1B
-
-$3.48
0.75
-
Price and volume
Market cap
$5.1B
Beta
0.75
52-week high
$49.82
52-week low
$22.71
Average daily volume
1.3M
Financial strength
Current ratio
6.95
Quick ratio
6.683
Long term debt to equity
42.106
Total debt to equity
44.367
Interest coverage (TTM)
-55.80%
Profitability
EBITDA (TTM)
-382.987
Management effectiveness
Return on assets (TTM)
-54.69%
Return on equity (TTM)
-123.08%
Valuation
Price to book
19.72
Price to tangible book (TTM)
19.72
Price to free cash flow (TTM)
-16.105
Free cash flow yield (TTM)
-6.21%
Free cash flow per share (TTM)
-2.772
Growth
Earnings per share change (TTM)
32.74%
3-year earnings per share growth (CAGR)
15.59%
What the Analysts think about Scholar Rock
Analyst ratings (Buy, Hold, Sell) for Scholar Rock stock.
Scholar Rock Financial Performance
Revenues and expenses
Scholar Rock Earnings Performance
Company profitability
Scholar Rock News
AllArticlesVideos
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·1 week ago
CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Business Wire·3 weeks ago
Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Scholar Rock stock?
Scholar Rock (SRRK) has a market cap of $5.1B as of March 22, 2026.
What is the P/E ratio for Scholar Rock stock?
The price to earnings (P/E) ratio for Scholar Rock (SRRK) stock is 0 as of March 22, 2026.
Does Scholar Rock stock pay dividends?
No, Scholar Rock (SRRK) stock does not pay dividends to its shareholders as of March 22, 2026.
When is the next Scholar Rock dividend payment date?
Scholar Rock (SRRK) stock does not pay dividends to its shareholders.
What is the beta indicator for Scholar Rock?
Scholar Rock (SRRK) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.